Which has preferable valuation and earnings, SLN or COAG?

Hemab Therapeutics has lower revenue, but higher earnings than Silence Therapeutics. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Silence Therapeutics $560K 555.07 -$88.61M -$1.59 N/A Hemab Therapeutics N/A N/A N/A N/A N/A

Do analysts recommend SLN or CALT?

Silence Therapeutics presently has a consensus target price of $55.00, suggesting a potential upside of 735.87%. Given Silence Therapeutics' stronger consensus rating and higher probable upside, equities analysts clearly believe Silence Therapeutics is more favorable than Calliditas Therapeutics AB (publ). Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Silence Therapeutics 1 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 1 Strong Buy rating(s) 2.80 Calliditas Therapeutics AB (publ) 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Silence Therapeutics (SLN) Competitors

$6.58 +0.17 (+2.65%)

As of 02:47 PM Eastern

Compare

SLN vs. MPLT, WVE, COAG, CALT, and OLMA

Should you buy Silence Therapeutics stock or one of its competitors? MarketBeat compares Silence Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Silence Therapeutics include Maplight Therapeutics (MPLT), WAVE Life Sciences (WVE), Hemab Therapeutics (COAG), Calliditas Therapeutics AB (publ) (CALT), and Olema Pharmaceuticals (OLMA). These companies are all part of the "pharmaceutical products" industry.

How does Silence Therapeutics compare to Maplight Therapeutics?

Silence Therapeutics (NASDAQ:SLN) and Maplight Therapeutics (NASDAQ:MPLT) are both small-cap pharmaceutical products companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, profitability, risk, analyst recommendations, media sentiment, institutional ownership, dividends and earnings.

Silence Therapeutics presently has a consensus price target of $55.00, suggesting a potential upside of 735.87%. Maplight Therapeutics has a consensus price target of $37.78, suggesting a potential upside of 22.77%. Given Silence Therapeutics' higher probable upside, equities research analysts clearly believe Silence Therapeutics is more favorable than Maplight Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Silence Therapeutics	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.80
Maplight Therapeutics	1 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	3 Strong Buy rating(s)	3.00

In the previous week, Maplight Therapeutics had 11 more articles in the media than Silence Therapeutics. MarketBeat recorded 11 mentions for Maplight Therapeutics and 0 mentions for Silence Therapeutics. Silence Therapeutics' average media sentiment score of 0.62 beat Maplight Therapeutics' score of 0.16 indicating that Silence Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Silence Therapeutics	Positive
Maplight Therapeutics	Neutral

Silence Therapeutics has higher revenue and earnings than Maplight Therapeutics. Silence Therapeutics is trading at a lower price-to-earnings ratio than Maplight Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Silence Therapeutics	$560K	555.07	-$88.61M	-$1.59	N/A
Maplight Therapeutics	N/A	N/A	-$161.15M	-$40.99	N/A

98.7% of Silence Therapeutics shares are held by institutional investors. 3.0% of Silence Therapeutics shares are held by company insiders. Comparatively, 3.8% of Maplight Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Maplight Therapeutics has a net margin of 0.00% compared to Silence Therapeutics' net margin of -8,943.86%. Maplight Therapeutics' return on equity of 0.00% beat Silence Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Silence Therapeutics	-8,943.86%	-105.34%	-52.79%
Maplight Therapeutics	N/A	N/A	N/A

Summary

Maplight Therapeutics beats Silence Therapeutics on 9 of the 15 factors compared between the two stocks.

How does Silence Therapeutics compare to WAVE Life Sciences?

Silence Therapeutics (NASDAQ:SLN) and WAVE Life Sciences (NASDAQ:WVE) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, profitability, analyst recommendations, media sentiment, earnings, risk, valuation and dividends.

In the previous week, WAVE Life Sciences had 4 more articles in the media than Silence Therapeutics. MarketBeat recorded 4 mentions for WAVE Life Sciences and 0 mentions for Silence Therapeutics. Silence Therapeutics' average media sentiment score of 0.62 beat WAVE Life Sciences' score of 0.32 indicating that Silence Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Silence Therapeutics	Positive
WAVE Life Sciences	Neutral

WAVE Life Sciences has a net margin of -255.70% compared to Silence Therapeutics' net margin of -8,943.86%. WAVE Life Sciences' return on equity of -56.76% beat Silence Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Silence Therapeutics	-8,943.86%	-105.34%	-52.79%
WAVE Life Sciences	-255.70%	-56.76%	-42.80%

Silence Therapeutics presently has a consensus target price of $55.00, suggesting a potential upside of 735.87%. WAVE Life Sciences has a consensus target price of $27.25, suggesting a potential upside of 343.45%. Given Silence Therapeutics' higher probable upside, analysts plainly believe Silence Therapeutics is more favorable than WAVE Life Sciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Silence Therapeutics	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.80
WAVE Life Sciences	1 Sell rating(s)	0 Hold rating(s)	14 Buy rating(s)	0 Strong Buy rating(s)	2.87

Silence Therapeutics has higher earnings, but lower revenue than WAVE Life Sciences. WAVE Life Sciences is trading at a lower price-to-earnings ratio than Silence Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Silence Therapeutics	$560K	555.07	-$88.61M	-$1.59	N/A
WAVE Life Sciences	$42.73M	27.67	-$204.38M	-$1.06	N/A

Silence Therapeutics has a beta of 1.48, indicating that its share price is 48% more volatile than the broader market. Comparatively, WAVE Life Sciences has a beta of -1.33, indicating that its share price is 233% less volatile than the broader market.

98.7% of Silence Therapeutics shares are held by institutional investors. Comparatively, 89.7% of WAVE Life Sciences shares are held by institutional investors. 3.0% of Silence Therapeutics shares are held by insiders. Comparatively, 24.3% of WAVE Life Sciences shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Summary

WAVE Life Sciences beats Silence Therapeutics on 9 of the 17 factors compared between the two stocks.

How does Silence Therapeutics compare to Hemab Therapeutics?

Silence Therapeutics (NASDAQ:SLN) and Hemab Therapeutics (NASDAQ:COAG) are both small-cap pharmaceutical products companies, but which is the better investment? We will contrast the two companies based on the strength of their media sentiment, dividends, institutional ownership, earnings, valuation, profitability, analyst recommendations and risk.

98.7% of Silence Therapeutics shares are held by institutional investors. 3.0% of Silence Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

In the previous week, Hemab Therapeutics had 3 more articles in the media than Silence Therapeutics. MarketBeat recorded 3 mentions for Hemab Therapeutics and 0 mentions for Silence Therapeutics. Hemab Therapeutics' average media sentiment score of 0.78 beat Silence Therapeutics' score of 0.62 indicating that Hemab Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Silence Therapeutics	Positive
Hemab Therapeutics	Positive

Silence Therapeutics presently has a consensus target price of $55.00, indicating a potential upside of 735.87%. Hemab Therapeutics has a consensus target price of $41.75, indicating a potential upside of 61.88%. Given Silence Therapeutics' higher probable upside, research analysts clearly believe Silence Therapeutics is more favorable than Hemab Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Silence Therapeutics	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.80
Hemab Therapeutics	0 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.80

Hemab Therapeutics has lower revenue, but higher earnings than Silence Therapeutics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Silence Therapeutics	$560K	555.07	-$88.61M	-$1.59	N/A
Hemab Therapeutics	N/A	N/A	N/A	N/A	N/A

Hemab Therapeutics has a net margin of 0.00% compared to Silence Therapeutics' net margin of -8,943.86%. Hemab Therapeutics' return on equity of 0.00% beat Silence Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Silence Therapeutics	-8,943.86%	-105.34%	-52.79%
Hemab Therapeutics	N/A	N/A	N/A

Summary

Hemab Therapeutics beats Silence Therapeutics on 6 of the 11 factors compared between the two stocks.

How does Silence Therapeutics compare to Calliditas Therapeutics AB (publ)?

Silence Therapeutics (NASDAQ:SLN) and Calliditas Therapeutics AB (publ) (NASDAQ:CALT) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their media sentiment, risk, analyst recommendations, dividends, institutional ownership, valuation, earnings and profitability.

98.7% of Silence Therapeutics shares are held by institutional investors. Comparatively, 2.8% of Calliditas Therapeutics AB (publ) shares are held by institutional investors. 3.0% of Silence Therapeutics shares are held by company insiders. Comparatively, 2.2% of Calliditas Therapeutics AB (publ) shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Silence Therapeutics has a beta of 1.48, suggesting that its share price is 48% more volatile than the broader market. Comparatively, Calliditas Therapeutics AB (publ) has a beta of 1.77, suggesting that its share price is 77% more volatile than the broader market.

In the previous week, Silence Therapeutics' average media sentiment score of 0.62 beat Calliditas Therapeutics AB (publ)'s score of 0.00 indicating that Silence Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Silence Therapeutics	Positive
Calliditas Therapeutics AB (publ)	Neutral

Silence Therapeutics presently has a consensus target price of $55.00, suggesting a potential upside of 735.87%. Given Silence Therapeutics' stronger consensus rating and higher probable upside, equities analysts clearly believe Silence Therapeutics is more favorable than Calliditas Therapeutics AB (publ).

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Silence Therapeutics	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.80
Calliditas Therapeutics AB (publ)	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Calliditas Therapeutics AB (publ) has higher revenue and earnings than Silence Therapeutics. Calliditas Therapeutics AB (publ) is trading at a lower price-to-earnings ratio than Silence Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Silence Therapeutics	$560K	555.07	-$88.61M	-$1.59	N/A
Calliditas Therapeutics AB (publ)	$1.60B	0.74	-$43.96M	-$1.85	N/A

Calliditas Therapeutics AB (publ) has a net margin of -30.18% compared to Silence Therapeutics' net margin of -8,943.86%. Silence Therapeutics' return on equity of -105.34% beat Calliditas Therapeutics AB (publ)'s return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Silence Therapeutics	-8,943.86%	-105.34%	-52.79%
Calliditas Therapeutics AB (publ)	-30.18%	-212.04%	-27.96%

Summary

Silence Therapeutics beats Calliditas Therapeutics AB (publ) on 11 of the 16 factors compared between the two stocks.

How does Silence Therapeutics compare to Olema Pharmaceuticals?

Olema Pharmaceuticals (NASDAQ:OLMA) and Silence Therapeutics (NASDAQ:SLN) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their media sentiment, analyst recommendations, institutional ownership, profitability, valuation, risk, dividends and earnings.

Olema Pharmaceuticals presently has a consensus target price of $44.10, indicating a potential upside of 313.54%. Silence Therapeutics has a consensus target price of $55.00, indicating a potential upside of 735.87%. Given Silence Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Silence Therapeutics is more favorable than Olema Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Olema Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	11 Buy rating(s)	0 Strong Buy rating(s)	2.71
Silence Therapeutics	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.80

Olema Pharmaceuticals has a beta of 1.98, meaning that its share price is 98% more volatile than the broader market. Comparatively, Silence Therapeutics has a beta of 1.48, meaning that its share price is 48% more volatile than the broader market.

Olema Pharmaceuticals has a net margin of 0.00% compared to Silence Therapeutics' net margin of -8,943.86%. Olema Pharmaceuticals' return on equity of -46.00% beat Silence Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Olema Pharmaceuticals	N/A	-46.00%	-41.22%
Silence Therapeutics	-8,943.86%	-105.34%	-52.79%

91.8% of Olema Pharmaceuticals shares are owned by institutional investors. Comparatively, 98.7% of Silence Therapeutics shares are owned by institutional investors. 12.6% of Olema Pharmaceuticals shares are owned by insiders. Comparatively, 3.0% of Silence Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Silence Therapeutics has higher revenue and earnings than Olema Pharmaceuticals. Olema Pharmaceuticals is trading at a lower price-to-earnings ratio than Silence Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Olema Pharmaceuticals	N/A	N/A	-$162.45M	-$2.02	N/A
Silence Therapeutics	$560K	555.07	-$88.61M	-$1.59	N/A

In the previous week, Olema Pharmaceuticals had 2 more articles in the media than Silence Therapeutics. MarketBeat recorded 2 mentions for Olema Pharmaceuticals and 0 mentions for Silence Therapeutics. Olema Pharmaceuticals' average media sentiment score of 0.96 beat Silence Therapeutics' score of 0.62 indicating that Olema Pharmaceuticals is being referred to more favorably in the media.

Company	Overall Sentiment
Olema Pharmaceuticals	Positive
Silence Therapeutics	Positive

Summary

Olema Pharmaceuticals and Silence Therapeutics tied by winning 8 of the 16 factors compared between the two stocks.

Get Silence Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding SLN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

SLN vs. The Competition

Export

Metric	Silence Therapeutics	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$310.84M	$2.96B	$6.42B	$12.48B
Dividend Yield	N/A	1.68%	2.69%	5.22%
P/E Ratio	-4.14	18.04	23.85	24.39
Price / Sales	555.07	296.06	520.29	116.29
Price / Cash	N/A	55.72	41.27	57.13
Price / Book	4.98	3.92	10.04	6.74
Net Income	-$88.61M	$75.85M	$3.56B	$337.03M
7 Day Performance	-4.08%	-2.17%	-1.09%	0.13%
1 Month Performance	N/A	N/A	N/A	-1.67%
1 Year Performance	19.64%	22.51%	28.56%	34.29%

Silence Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
SLN Silence Therapeutics	2.8133 of 5 stars	$6.58 +2.7%	$55.00 +735.9%	+18.5%	$310.84M	$560K	N/A	100
MPLT Maplight Therapeutics	3.8026 of 5 stars	$29.17 +1.5%	$35.50 +21.7%	N/A	$1.24B	N/A	N/A	109	Analyst Forecast Analyst Revision
WVE WAVE Life Sciences	2.7397 of 5 stars	$6.40 +0.3%	$27.25 +325.8%	-11.4%	$1.23B	$42.73M	N/A	240
COAG Hemab Therapeutics	4.7699 of 5 stars	$27.53 +6.3%	$41.75 +51.7%	N/A	$1.22B	N/A	N/A	72	News Coverage Short Interest Increase
CALT Calliditas Therapeutics AB (publ)	N/A	$40.00 flat	N/A	N/A	$1.19B	$1.60B	N/A	180

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:SLN) was last updated on 6/4/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Silence Therapeutics (SLN) Competitors

SLN vs. MPLT, WVE, COAG, CALT, and OLMA

How does Silence Therapeutics compare to Maplight Therapeutics?

Summary

How does Silence Therapeutics compare to WAVE Life Sciences?

Summary

How does Silence Therapeutics compare to Hemab Therapeutics?

Summary

How does Silence Therapeutics compare to Calliditas Therapeutics AB (publ)?

Summary

How does Silence Therapeutics compare to Olema Pharmaceuticals?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SLN vs. The Competition

Silence Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Silence Therapeutics (SLN) Competitors

SLN vs. MPLT, WVE, COAG, CALT, and OLMA

How does Silence Therapeutics compare to Maplight Therapeutics?

Do analysts rate SLN or MPLT?

Does the media prefer SLN or MPLT?

Which has better valuation & earnings, SLN or MPLT?

Do institutionals & insiders hold more shares of SLN or MPLT?

Is SLN or MPLT more profitable?

Summary

How does Silence Therapeutics compare to WAVE Life Sciences?

Does the media favor SLN or WVE?

Is SLN or WVE more profitable?

Do analysts prefer SLN or WVE?

Which has stronger valuation and earnings, SLN or WVE?

Which has more volatility and risk, SLN or WVE?

Do institutionals and insiders have more ownership in SLN or WVE?

Summary

How does Silence Therapeutics compare to Hemab Therapeutics?

Do institutionals & insiders have more ownership in SLN or COAG?

Does the media prefer SLN or COAG?

Do analysts prefer SLN or COAG?

Which has preferable valuation and earnings, SLN or COAG?

Is SLN or COAG more profitable?

Summary

How does Silence Therapeutics compare to Calliditas Therapeutics AB (publ)?

Do institutionals & insiders hold more shares of SLN or CALT?

Which has more volatility and risk, SLN or CALT?

Does the media prefer SLN or CALT?

Do analysts recommend SLN or CALT?

Which has stronger earnings & valuation, SLN or CALT?

Is SLN or CALT more profitable?

Summary

How does Silence Therapeutics compare to Olema Pharmaceuticals?

Do analysts recommend OLMA or SLN?

Which has more risk & volatility, OLMA or SLN?

Is OLMA or SLN more profitable?

Do insiders and institutionals believe in OLMA or SLN?

Which has better valuation & earnings, OLMA or SLN?

Does the media favor OLMA or SLN?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SLN vs. The Competition

Silence Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools